证券日报网讯 8月28日晚间，上海医药发布公告称，公司第八届董事会第二十四次会议审议通过了 《2025年半年度报告及摘要》等。 （文章来源：证券日报） ...

上海医药（601607）(02607)公布2025年中期业绩，营业收入约1415.93亿元，同比增长1.56%;归属于上 市公司股东的净利润约44.59亿元，同比增长51.56%;基本每股收益1.2元。 公告称，归母净利增长主要是由于对和黄药业会计核算由合营企业权益法核算变更为按子公司核算而产 生一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为27.82亿元，同比下降 2.06%。 ...

Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 141.59 billion yuan for the first half of 2025, with a year-on-year growth of 1.56%, and a net profit of 4.46 billion yuan, reflecting a significant increase of 51.56% [1] Group 1: Financial Performance - The pharmaceutical manufacturing segment generated sales of 12.16 billion yuan, while the pharmaceutical commercial segment achieved sales of 129.43 billion yuan, with the latter growing by 2.17% year-on-year [1] - The company’s net profit attributable to shareholders reached 4.46 billion yuan, with contributions from the industrial segment at 1.15 billion yuan and the commercial segment at 1.79 billion yuan [1] Group 2: R&D and Innovation - R&D investment totaled 1.15 billion yuan, accounting for 9.44% of the pharmaceutical manufacturing sales, with 959 million yuan specifically allocated for R&D expenses [2] - The company has a pipeline of 56 new drugs, including 44 innovative drugs, with significant progress in clinical trials for several candidates [2] - The company is advancing its research platforms, achieving milestones in drug discovery and clinical trials, including the completion of Phase II trials for multiple candidates [2] Group 3: Strategic Initiatives - The company is enhancing its open-source innovation ecosystem by collaborating with high-growth enterprises and establishing a drug technology validation center with Shanghai Jiao Tong University [3] - The company is focusing on marketing transformation and lean management to improve industrial operations, achieving cost savings of approximately 6.98 million yuan through centralized procurement [4] Group 4: Business Expansion - The company completed the acquisition of a 10% stake in Hehuang Pharmaceutical, which has shown growth in key performance indicators [5] - The company is implementing a "big health OTC + new retail" strategy, including the formation of a professional live-streaming team to explore new business models [6] Group 5: Commercial Performance - The pharmaceutical commercial segment is leveraging technological innovation and digitalization to maintain growth, with significant increases in contract sales and strategic partnerships [7][8] - The import agency business added 25 new product specifications, generating sales of 17.5 billion yuan, a year-on-year increase of 11.7% [8] - The company launched an integrated new retail strategy, enhancing patient-centered services through its retail network and supply chain [8]

该信息由智通财经网提供 智通财经APP讯，上海医药(02607)公布2025年中期业绩，营业收入约1415.93亿元，同比增长1.56%;归 属于上市公司股东的净利润约44.59亿元，同比增长51.56%;基本每股收益1.2元。 公告称，归母净利增长主要是由于对和黄药业会计核算由合营企业权益法核算变更为按子公司核算而产 生一次性特殊收益所致，扣除上述事项等一次性特殊损益后的归母净利润为27.82亿元，同比下降 2.06%。 ...

Core Viewpoint - Shanghai Pharmaceuticals reported a revenue of 141.593 billion RMB for the first half of 2025, reflecting a year-on-year growth of 1.56% [1] Revenue Breakdown - The pharmaceutical manufacturing segment generated sales of 12.160 billion RMB, a decrease of 4.50% year-on-year [1] - The pharmaceutical distribution segment achieved sales of 129.433 billion RMB, an increase of 2.17% year-on-year [1] Profit Analysis - The net profit attributable to shareholders was 4.459 billion RMB, representing a year-on-year increase of 51.56%, primarily due to a one-time special gain from changing the accounting treatment of a joint venture to a subsidiary [1] - Excluding one-time special gains and losses, the net profit attributable to shareholders was 2.782 billion RMB, showing a year-on-year decline of 2.06% [1] Strategic Focus - The company emphasizes steady progress and innovation, focusing on strengthening core competencies and enhancing development momentum through a "three horizontal and three vertical" development system [1] - Shanghai Pharmaceuticals has been recognized in the Fortune Global 500 and ranked 407th, while also being listed among the top 25 most valuable pharmaceutical brands globally, ranking 19th [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容 而產生或因依賴該等內容而引致的任何損失承擔任何責任。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607) 截至2025年6月30日六個月未經審計中期業績公告 上海醫藥集團股份有限公司（「本公司」）董事會（「董事會」）欣然發佈本公司及其附屬公司 （合稱「本集團」）截至2025年6月30日六個月的中期業績。該中期業績乃根據中國企業會 計準則編製，未經審計。董事會及審計委員會已審閱並確認此中期業績。 本公司截至2025年6月30日六個月的中期報告全文附於本公告後。正式中期報告 將於適當時候在香港聯合交易所有限公司的網站(www.hkexnews.hk)和本公司網站 (www.sphchina.com)刊登。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，二零二五年八月二十九日 於本公告日期，本公司的執行董事為楊秋華 ...

智通财经APP讯，上海医药(601607.SH)披露2025年半年度报告，报告期公司实现营收1415.93亿元，同 比增长1.56%;归母净利润44.59亿元，同比增长51.56%;扣非净利润21亿元，同比下降22.38%;基本每股收 益1.20元。 ...

北京商报讯（记者王寅浩实习记者宋雨盈）8月28日，上海医药发布公告称，2025年上半年实现营业收 入1415.93亿元，同比增长1.56%；归属于上市公司股东的净利润为44.59亿元，同比增长51.56%；归属 于上市公司股东的扣除非经常性损益的净利润为21亿元，同比下降22.38%。 （文章来源：北京商报） ...

智通财经APP讯，上海医药(601607.SH)披露2025年半年度报告，报告期公司实现营收1415.93亿元，同 比增长1.56%;归母净利润44.59亿元，同比增长51.56%;扣非净利润21亿元，同比下降22.38%;基本每股收 益1.20元。 ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十四次會議決議公告》、《上海醫藥集 團股份有限公司關於上海上實集團財務有限公司2025半年度風險持續評估報告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 8 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文 ...